PTC Therapeutics
Clinical trials sponsored by PTC Therapeutics, explained in plain language.
A biopharmaceutical company focused on rare genetic disorders.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
Can a new pill quiet the inflammation of rheumatoid arthritis?
Disease control Not yet recruitingThis trial is testing an experimental drug called PTC844 in people with active rheumatoid arthritis, a condition where the immune system attacks the joints, causing pain and swelling. The study aims to see if PTC844 is safe, how it moves through the body, and whether it can reduc…
Phase 2 • Sponsor: PTC Therapeutics • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Experimental drug aims to halt rare neurological decline
Disease control Not yet recruitingThis Phase 3 trial tests whether vatiquinone can slow the progression of Friedreich's ataxia, a rare genetic disorder that damages the nervous system and impairs movement. About 120 adults with moderate symptoms will take the drug for 24 months. Researchers will measure changes i…
Phase 3 • Sponsor: PTC Therapeutics • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC